Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: S&P Capital IQ Quantitative Report
$92.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Abbott Laboratories's MitraClip Device now approved in Canada


Wednesday, 30 Apr 2014 08:01am EDT 

Abbott Laboratories:Says its MitraClip therapy has received Health Canada approval, with a treatment option that can significantly improve symptoms, disease progression and quality of life for certain people with a heart condition called mitral regurgitation.Treatment with the MitraClip device can be effective in reducing the symptoms associated with severe MR, such as shortness of breath and fatigue, which may help people lead a more active lifestyle. 

Company Quote

42.06
-0.27 -0.64%
15 Aug 2014